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Abstract 
ST3GAL5-CDG is a rare syndrome which is caused by variant GM3 synthases, the enzyme involved in 
the biosynthesis of a-b-c-series gangliosides. Here we report a novel homozygous ST3GAL5 variant, 
p.Gly342Ser, in a patient suffering from failure to thrive, severe hearing, visual, motor, and cognitive
impairment, and respiratory chain dysfunction. A GM3 synthase assay towards the natural acceptor 
substrate lactosylceramide was performed upon transfection in HEK-293T cells of expression 
plasmids carrying wild type and mutated ST3GAL5 cDNAs. The assay revealed a complete loss of 
enzyme activity. Identical results were obtained with the other four ST3GAL5 variants which have 
been reported to be pathogenic. HEK-293T clones permanently expressing HaloTag-ST3GAL5 carrying 
each of the five variants were assessed by quantitative PCR, flow cytometry, western blotting, and 
confocal microscopy. The results indicated that transcription, translation, stability, and intracellular 
localization of the tagged protein were identical to those of the wild type construct. Compared with 
the very mild phenotype of st3gal5 KO mouse models, the results suggest that unknown 
mechanisms, in addition to the lack of a-b-c-series gangliosides, contribute to the syndrome. Direct 
enzyme assay upon transfection in model cells appears to be an effective tool for characterizing 
variants of glycosyltransferases involved in glycosphingolipid biosynthesis. 
Introduction 
ST3GAL5 (HGNC 10872, MIM# 604402) belongs to the wide family of sialyltransferases, the enzymes 
able to transfer sialic acid from the donor CMP-NeuAc to the oligosaccharide chain of glycoproteins 
and glycosphingolipids (Audry et al. 2011). ST3GAL5 specifically links the -2 position of sialic acid to 
the 3-position of galactose in lactosylceramide (LacCer), which is considered the relevant natural 
acceptor, and forms ganglioside GM3. ST3GAL5 is also reported as the enzyme able to use 
galactosylceramide as an acceptor, forming ganglioside GM4 (Uemura et al. 2014). It is thus 
commonly known as GM3 synthase, or GM3/GM4 synthase. GM3 is the precursors of all other 
gangliosides of the a-, b-, and c-series, such as GM2, GM1, GD1a, GD1b and GT1b. In 2004, a non-
sense variant in ST3GAL5, p.Arg288ter (R288*), was found in family members of the Amish 
community (Simpson et al. 2004) and was reported to be the cause of a severe neurologic syndrome 
characterized by normal gestation and delivery, early onset of symptoms, drug-resistant epilepsy, 
failure to thrive, and general motor and cognitive impairment. This finding provided the first 
evidence for a congenital disorder of glycosylation that affected the biosynthesis of complex 
glycosphingolipids. More recently (Fragaki et al. 2013), the same variant was reported in two French 
siblings who were supposedly affected by a mitochondrial disease, because they exhibited increased 
values of blood lactate and because there was a dysfunction of the respiratory chain in the cultured 
fibroblasts of the patients. Three additional ST3GAL5 variants have been reported in the last few 
years (Figure 1). One (Boccuto et al. 2014) is a missense substitution, p.Glu355Lys (E355K), described 
in the members of an Afro-American family affected by a disorder previously named “salt and 
pepper” syndrome due to a typical cutaneous dyspigmentation associated to the neurological 
symptoms. This sign was later confirmed even in the Amish patients (Wang H. et al. 2016). The other 
examples are represented by a compound variant, p.Cys195Ser;p.Gly201Ala (C195S/G201A), 
reported in two Korean siblings suffering from a slightly less severe neurological syndrome, which 
was characterized by a delayed onset of symptoms and by the absence of seizures (Lee et al. 2016).  
In all the reported cases, the consequences of the variant were characterized by mass spectrometric 
analysis of gangliosides from blood or fibroblasts samples from the affected children. No information 
is currently available on the enzyme activity in vitro, nor on the stability and subcellular localization 
of these ST3GAL5 variants. Of the two st3gal5 knock-out mouse models generated in the past, the 
earlier study (Yamashita et al. 2003) revealed a phenotype that was generally normal except for 
increased insulin sensitivity. In the latter study (Yoshikawa et al. 2009), the mice displayed hearing 
loss which resulted from cell degeneration in the organ of Corti in the cochlea (Yoshikawa et al. 
2015). Based on these results, some patients of the Amish community were re-evaluated, and this 
provided evidence of several cases of cochlear impairment (Yoshikawa et al. 2015). This suggested 
that the specific defect found in the KO mice could be a single sign of the much more complex human 
syndrome. 
Here, we report a novel homozygous ST3GAL5 missense variant detected in an Italian patient who 
exhibited several symptoms common to those previously described in the other ST3GAL5-CDG 
patients. To biochemically characterize the novel and previous ST3GAL5 variants, we cloned the wild 
type (WT) ST3GAL5 gene in an expression vector and generated plasmids carrying all five variants 
known to be pathogenic. The enzyme activity towards the acceptor LacCer was measured in 
transfected HEK-293T cells. Moreover, we constructed tagged versions of the mutated cDNAs and 
established permanent HEK-293T transfectants, which were studied to measure the amount of 
transcript and protein expressed as well as the protein’s intracellular localization. The biochemical 
characterization of pathogenic ST3GAL5 variants is discussed with regard to the clinical features of 
the patients or the phenotype of KO mouse models. 
Results 
Features of the patient harboring the c.1024G>A (G342S) variant 
The proband, a 13 year-old female, is the only child of healthy parents, both from a village of about 
5.000 inhabitants in the South of Italy. Pregnancy was uneventful and she was born at term by 
vaginal delivery. APGAR score was 8-9. Birth weight was 3240 grams (50th centile), length 49 cm (25th 
centile), and head circumference was 35 cm (10th centile). In the first week of life, she had severe 
neonatal jaundice (which was treated with phototherapy), moderate generalized hypotonia, and 
patent foramen ovale. Also, unclear responses were reported in the hearing screening test. Between 
four and twelve months of age, a severe bilateral sensorineural hearing loss was documented, and 
she started wearing external retroauricular hearing devices. She soon developed failure to thrive and 
a severe psychomotor delay. She had convergent strabismus and did not follow objects with her 
eyes. Regarding fundus oculi, visual evoked potentials and electroretinogram were normal, but 
severe bilateral central visual damage was diagnosed. At about two years of age, electromyography, 
brain MRI, karyotype, subtelomeric rearrangements, CGH array, and transferrin isoelectrofocusing 
tests were performed together with the determination of plasma very long chain fatty acids and 
amino acids, plasma and cerebrospinal fluid alanine, and cerebrospinal fluid lactate and pyruvate. 
Outcomes were all within the normal ranges. Conversely, mildly abnormal results were found for 
plasma alanine aminotransferase and lactate dehydrogenase, bilirubin, blood pyruvate and blood 
and urinary lactate (Table I). At the age of 2 years, studies performed on cultured fibroblasts and 
muscle biopsy suggested the diagnosis of pyruvate kinase and respiratory chain complex III 
deficiency, while muscle histology was normal. 
The patient had gastroesophageal reflux with recurrent vomiting; swallowing was studied and 
appeared normal and well-coordinated. Gastrostomy was not performed. At the age of 18 months, 
the EEG showed multifocal epileptiform activity, prevalently during sleep without clinical seizures. At 
18 months of life she developed epilepsy treated only with Phenobarbital and later on, at the age of 
3 years, treated with the addition of Topiramate, since she had developed a status epilepticus. She 
received a diagnosis of sickle-cell anemia at 3 years of age and was then followed-up for this disease. 
Starting at about 8 years of age, her neurological picture was dominated by continuous and 
apparently involuntary movements (Supplementary Video). Since the clinical picture and evolution 
were not convincing for a mitochondrial disorder, at the age of 10 years, a clinical exome was 
performed and a homozygous variant of the ST3GAL5 gene was identified, Chr2(GRCh38): 
g.85840377C>T; NM_003896.3(ST3GAL5): c.1024G>A; NP_003887.3: p.Gly342Ser (G342S), together
with the confirmation of sickle-cell anemia due to the homozygous missense substitution p.Glu7Val 
(Q7V) in the HBB gene. The parents resulted heterozygous carriers of both substitution in the 
ST3GAL5 and HBB genes and pQ7V in the HBB gene. All identified variants were confirmed by direct 
DNA sequencing (Supplementary Figure S1). 
At present, the growth delay is severe (Table I). A dysmorphic facial feature has become 
progressively more evident (Figure 2A). Beginning at 9 years of age, she developed freckle-like hyper-
pigmented macules ranging in size from 2 to 10 mm in diameter that were located bilaterally on the 
plantar side of her feet (Figure 2B). The brain MRI performed again at 8 years of age did not show 
atrophy or other abnormalities (Figure 2C). However, this brain has a slow rate of growth as evidence 
by the progressive reduction of centiles over the years.  
Loss of GM3 synthase activity in ST3GAL5 variants 
To determine the functional consequences of the novel G342S variant, we directly measured GM3 
synthase activity using the natural acceptor substrate LacCer in-vitro. With this goal, the ST3GAL5 
coding sequence was cloned in the expression vector pcDNA3 under the control of the strong CMV 
promoter. Together with a trace amount of a reporter luciferase expression plasmid, the construct 
was transiently transfected into HEK-293T cells, which are able to replicate the SV40 origin present 
in the plasmids. Homogenates of transfected cells were then used as the enzyme source in reactions. 
In preliminary experiments, ST3GAL5 activity appeared undetectable in HEK-293T cells under the 
assay conditions used, irrespective of the protein concentration. We measured the GM3 synthase 
activity of WT ST3GAL5 and of p.His104Arg (H104R) substitution (NM_003896.3: c.311C>G), known 
to be present in the healthy population (gnomAD Minor Allele Frequency 21%), together with that of 
the G342S variant and the activity of the other variants responsible for ST3GAL5-CDG. Although the 
reporter luciferase activity was comparable in all samples, GM3 synthase was high and proportional 
to the amount of cellular proteins only in the assay of WT and H104R constructs. No activity was 
detected with all the other ST3GAL5 variants, nor in mock transfected cells, even with the highest 
amounts of homogenate proteins (Figure 3A).  
We also measured GM3 synthase activity towards LacCer of HEK-293T clones permanently 
expressing WT or variant ST3GAL5 fused with the HaloTag (see next paragraph). In the WT HaloTag-
ST3GAL5 clones, the activity was high and linear over a protein range of 0.2 to 80 g of protein 
homogenate per assay (Figure 3B). To calculate the potential residual activity in the mutated 
enzymes, we used 80 g of protein homogenate from the clones expressing the highest amount of 
each variant HaloTag-ST3GAL5 (fuchsia lines in Figure 4) per assay. In parallel, we used 0.2 and 0.4 g 
of protein homogenate from a clone expressing an intermediate level of WT fusion protein (brown 
line in Figure 4). Incorporation of sialic acid into LacCer by all HaloTag-ST3GAL5 variants was 
negligible, similar to that measured with mock-transfected HEK-293T cells and much lower than that 
obtained with 0.4 g of the WT homogenate (Figure 3C). We concluded that the residual activity of 
each ST3GAL5 variant, if any, is less than 0.5%.  
Transcription, translation, and apparent stability of ST3GAL5 expressed in HEK-293T cells are not 
affected by G342S or other pathogenic substitutions causing ST3GAL5-CDG 
To investigate the mechanisms responsible for the lack of activity in HEK-293T cells transiently 
transfected with the variant ST3GAL5 cDNAs, we generated HEK-293T cells permanently expressing a 
tagged version of the WT and variant ST3GAL5 cDNAs. To this aim, the different ST3GAL5 cDNAs 
were cloned in frame downstream of the HaloTag in a proper expression vector and co-transfected 
with a puromycin-resistance plasmid. From the many colonies resulting from puromycin selection, 
20-25 colonies for each construct were screened by fluorescence microscopy after labeling with the 
HaloTag ligand TMR. Five to seven positive colonies, apparently homogeneous by visual inspection 
with the fluorescence microscopy, were collected and re-analyzed by flow cytometry after labeling 
with TMR. Fluorescence in the wild type clones appeared relatively homogeneous, with positive cells 
ranging between 70 and 90%. The intensity of fluorescence was variable, which is typical of stable 
clones obtained by random insertion of exogenous DNA into the genome that determines 
heterogeneous levels of transcriptional activity (Figure 4, left panels). To assess this aspect, the 
amount of ST3GAL5 transcript was determined for each clone by real time PCR (Supplementary 
Figure S2) and plotted against the respective mean fluorescence intensity (Figure 4 right panels). As 
expected, the mean fluorescence intensity of each clone was roughly proportional to the level of 
transcript. It was notable that Ct values referred to GAPDH for the ST3GAL5 transcript in the clones 
ranged 4-8 versus 15-16 in mock transfected HEK-293T cells. This indicated that the amount of 
ST3GAL5 mRNA in the cell line was minimal (215-216-fold less than GAPDH) and negligible when 
compared with the amount driven in by transfected cells. The fluorescence profiles displayed by 
individual clones obtained upon transfection with G342S or all other HaloTag-ST3GAL5 variants 
overlapped those found with the WT clones (Figure 4, left panels). The ratio between the mean 
fluorescence intensities and the transcript levels in the individual clones was also similar in cells 
expressing WT or variant HaloTag-ST3GAL5. 
To assess that the fluorescence detected in the cell clones is due to Halo tagged ST3GAL5, the 
proteins extracted from the cell membranes by detergent treatment were analyzed by western blot 
using anti HaloTag antibody for detection. A single band of about 85 kDa was detected in the clones 
expressing WT as well as the G342S variant. Identical results were obtained with the C195S-, G201A-, 
and E355K- HaloTag-ST3GAL5, while the protein expressed by the clones of the R288* variant 
appears as a band at about 70 kDa. Sometimes an additional band was evident, especially in a single 
WT clone, about 20 kDa shorter than 85 kDa (Figure 5). The nature of such minor band is unknown, 
and we speculate that it is a side effect of the overexpression, since it is appreciable only in the 
clones expressing the highest levels of the construct. Considering the molecular weight of the 
HaloTag (33 kDa), the size of WT and sense-ST3GAL5 variants appears to be about 52 kDa, as 
expected for the cloned ST3GAL5 (about 48 kDa) plus the N-glycans known to be present (Zava et al. 
2010), while the non-sense variant could be to a truncated protein of about 35 kDa. The results 
suggest that transcription, translation, and apparent stability in HEK-293T cells are not affected by 
the variants.  
The intracellular localization of ST3GAL5 variants overlaps that of the WT protein 
To compare the intracellular localization of the different HaloTag-ST3GAL5, we transiently 
transfected a representative clone for each variant or WT transfectant with a chimera in which GFP 
was cloned downstream of the N-terminal portion of ST3GAL5 encompassing the signal sequence for 
Golgi localization and retention (Uemura et al. 2015). Analysis of green (GFP) and red (TMR-labeled 
HaloTag) fluorescence through confocal microscopy revealed a bulk (70-90%) of red stained cells 
with a typical perinuclear pattern, and a minority (20-30%) of green-stained cells showing an 
apparently identical pattern. Many red cells did not appear green, as a consequence of the limited 
efficiency of the transient transfection, while only a few cells appeared only green and not red 
(Supplementary Figure S3). In the cells expressing both green and red fluorescence at comparable 
levels, the two colors totally overlapped, indicating co-localization of native and HaloTag-ST3GAL5 in 
both WT and variant clones (Figure 6). We concluded that all ST3GAL5 variants are localized in HEK-
293T cells as the WT protein. To better localize HaloTag-ST3GAL5 inside the cells, TMR-labeled clones 
were fixed, permeabilized, and treated with anti-Golgin97 (a Golgi apparatus marker) or anti-PDI 
(protein disulfide isomerase, an endoplasmic reticulum marker) antibodies, followed by a secondary 
FITC-labeled antibody. Confocal microscopy analysis revealed a substantial overlapping of HaloTag-
ST3GAL5 with Golgin97 but not with PDI, in both WT and all variants, irrespective of the mutation 
(Figure 7). 
Discussion 
In this paper, we reported a novel missense substitution of the ST3GAL5 gene. The result of this 
mutation is a complete loss of GM3 synthase activity. Transcription, translation, localization and 
apparent stability of the variant protein appeared undistinguishable from those of the WT protein, at 
least in the HEK-293T cell model. Parallel characterization of the other ST3GAL5 variants reported so 
far and associated with a similar severe neurological syndrome, provided identical results. All 
variants appeared transcribed, translated and localized as the WT protein, but without any 
detectable GM3 synthase activity. Considering the sensitivity of the enzyme assay, we concluded that 
the residual activity of the variants, if any, is less than 0.5%. From the clinical point of view, the 
patient carrying the novel G342S variant was similar to the patients in previous reports who carried 
other variants. In fact, they all presented normal pregnancy and delivery, early onset of symptoms, 
failure to thrive, delayed motor development, and severe neurological impairment (Simpson et al. 
2004, Fragaki et al. 2013, Boccuto et al. 2014, Lee et al. 2016, Wang H. et al. 2016). However, some 
common or differential aspects could be observed. Hearing impairment is emerging as the truly 
distinctive sign common to all ST3GAL5-CDG patients and even KO mice. The presence of this sign 
was suspected after the neonatal screening test, and later it was diagnosed by auditory tests in all 
tested patients. Deafness was then recognized at an older age. This symptom is related to the lack of 
GM3 and other ganglio-series gangliosides which have a role in the epithelium of the organ of Corti 
(Yoshikawa et al. 2015, Inokuchi et al. 2017). A mild elevation of blood lactate and signs of 
respiratory chain dysfunction are also emerging as distinctive symptoms, since these have been 
found in all tested patients. This is very intriguing, because gangliosides are known to be 
undetectable in mitochondria and particularly in brain mitochondria (Kiebish et al. 2008). 
Consequently, the simple lack of gangliosides, or even the accumulation of their by-products, seems 
insufficient to explain a mitochondrial symptom, which was not reported in the KO mice. The energy 
failure appeared clinically irrelevant in the Italian patient, but its role in the syndrome could not be 
ruled out and deserves future investigation. At 18 months of age, the patient developed clinical 
seizures sensitive to Phenobarbital, which evolved to a status epilepticus controlled by the addition 
of Topiramate. This condition appears intermediate between the pharmacoresistant epilepsy 
reported in the R288* patients (Simpson et al. 2004, Fragaki et al. 2013) and the lack of seizures in 
the Korean siblings carrying the C195S/G201A compound substitutions (Lee et al. 2016). Epilepsy 
seems to be variable in the syndrome and potentially dependent on the variant. In general, the 
R288* variant appears to produce the most severe form of the syndrome, while the symptoms from 
the compound variants C195S/G201A are slightly milder. In fact, these patients not only lack seizures 
but show a delay in the onset of the symptoms and developmental regression, and they have 
relatively lower motor-neuro impairment (one patient is reported able to walk few steps). 
Surprisingly, both the C195S and G201A variants lead to a complete loss of GM3 synthase activity, 
indicating that the milder phenotype is not due to a residual enzyme function. The phenotype of the 
Italian patient here reported is somewhat intermediate. The occurrence of cutaneous 
dyspigmentation, known as a common but not distinctive sign (Boccuto et al. 2014, Wang et al. 
2013), is also confirmed in this patient. Its pathogenesis is largely unclear but could be related to the 
accumulation of ceramide-based precursors or by-products associated with the derangements of 
glycosphingolipid metabolism, due to their role in melanocyte biology (Wang P. et al. 2016, Lee et al. 
2011, Saha et al. 2009). It is worth recalling that in the brain of st3gal5 KO mice, missing gangliosides 
are replaced by a relevant amount of 0-series gangliosides, such as GM1b and GD1, without 
accumulation of neutral glycosphingolipids (Yamashita et al. 2003). While fibroblasts from KO mice 
display a similar pattern (Shevchuk et al. 2007, Nagahori et al. 2013), human fibroblasts from R288* 
(Liu et al. 2008, Fragaki et al. 2013), and E355K (Boccuto et al. 2014) patients lack any ganglioside and 
accumulate globosides. These findings probably constitute the basis for explaining the discrepancy 
between the devastating features of the human ST3GAL5-CDG and the very mild phenotype of KO 
mice. This view underlies the hypothesis that gangliosides are functionally interchangeable, and this 
is corroborated by the finding that single glycosyltransferase KO mice (Takamya et al. 1996, Sheikh et 
al. 1999, Kawai et al. 2001, Okada et al. 2002, Handa et al. 2005) present a rather mild phenotype, 
while double KO animals (Kawai et al. 2001, Inoue et al. 2002, Ohmi et al. 2009, Yamashita et al. 
2005) are more severely impaired. Moreover, a wider derangement of glycosylation may occur and 
affect the glycan profile of protein in addition to that of sphingolipid precursors or by products. In 
this regard, in fibroblasts from E355K patients (Boccuto et al. 2014) the profile of N-linked glycans 
was shifted toward increased abundance of complex and sialylated structures, and that of major O-
linked glycans also shifted toward more highly sialylated forms. In embryonic fibroblasts from st3gal5 
KO mice (Shevchuc et al. 2007, Nagahori et al. 2013) the expression levels of total glycoprotein N-
glycans increased slightly over the WT. 
In principle, gene variants can be responsible for a given phenotype either through the loss or the 
gain of function of the gene product, or both. The biochemical characterization of ST3GAL5 variants 
documented the former possibility and left open the latter. In fact, the finding that all variants are 
properly transcribed, translated, and localized does not rule out that the presence of the mutated 
and inactive protein is necessary to produce the severe disease, although through a mechanism 
unknown at present. Moreover, if the total lack of residual activity is necessary to give rise to the 
known syndrome, the partial inactivation may give rise to a very different clinical picture, probably 
milder, perhaps restricted to the hearing function. The presence of alleles coding a partially active 
GM3 synthase and responsible for milder clinical syndromes could be suspected in the population 
starting from children suffering bilateral unexplained congenital cochlear hypoacusia. Recently, 
ST3GAL3 variants (Hu et al. 2011, Edvardson et al. 2013) and B4GALNT1 variants (Harlaka et al. 2013, 
Boukhris et al. 2013, Wakil et al. 2014) were identified as causes of West syndrome and hereditary 
spastic paraplegia 26, respectively. This suggests that alteration of ganglioside biosynthesis may 
account for various unidentified diseases, as recently reviewed (Trinchera et al. 2018). 
Our approach allowed us to directly detect the effect of each substitution at the protein level, 
without the need for patient material. In fact, HEK-293T cells are able to sustain episomal replication 
of plasmids carrying the polyoma-SV40 origin of replication. Placing cDNA sequences in such plasmid 
vectors under the control of the strong CMV promoter provides abundant expression of the target 
sequences upon transfection into such cells. Using the homogenate from transfected cells with the 
natural acceptor substrate LacCer, we were able to quantify the potential residual activity in a very 
small range. Combined with the power of new generation sequencing, this approach has the 
potential to help recognize unexplained inherited syndromes as novel disorders of ganglioside 
biosynthesis. 
Materials and methods 
Genomic DNA analysis 
After genetic counselling and written informed consent, genomic DNAs of patient and both parents 
were extracted from peripheral blood using a commercial kit. Exons and the splice sites flanking 
regions were enriched using the Illumina TruSightOne enrichment kit (Illumina, San Diego, CA), 
targeting a subset of the human exome (4,813 genes; 62,183 exons) followed by 150bp paired-end 
sequencing on the NextSeq500 platform (Illumina, San Diego, CA). To prioritize variants a sequential 
filtering strategy was applied, retaining only variants with the following characteristics: 1. potential 
effect on protein and transcript; 2. consistency with the patient’s phenotype according to the Human 
Phenotype Ontology classification (www.human-phenotype-ontology.org/); 3. consistency with the 
suspected inheritance model (autosomal recessive or de novo); 4. frequency in general population 
consistent with prevalence and incidence of the disease (ExAC and gnomAD) and showing a 
pathogenic mechanism corresponding to the one expected for the disease. Variants were classified 
on the basis of ACMG guidelines (Richards et al., 2015) and following modifications (Nykamp et al., 
2017). Visual inspection was performed by Alamut Visual Software (http://www.interactive-
biosoftware.com/alamut-visual/). The potential causative variants were subsequently confirmed by 
Sanger sequencing. Variant information has been submitted to ST3GAL5 Locus Specific Database and 
is available at https://databases.lovd.nl/shared/variants/0000378693#00025300. 
DNA constructs 
ST3GAL5 coding sequence was amplified by PCR using cDNA prepared by reverse transcription of 
poly(A)+ RNA extracted from Human brain (Clontech) in the presence of FidelyTaq DNA polymerase 
(Affymetrix) according to the manufacturer’s protocol. Amplification was for 30 cycles and annealing 
temperature 64°C. The primer pair used is reported in Supplementary Table S1. The obtained cDNA 
was purified (Wizard SV Gel and PCR Clean-Up system, Promega), digested with HindIII and XbaI 
(sites added in the primer sequences) and cloned in the corresponding sites of pcDNA3 vector. 
Clones were then submitted to direct DNA sequencing to assess fidelity. The obtained plasmid was 
mutated using QuikChange II-E Site-Directed Mutagenesis Kit (Agilent Technologies) and the reported 
primer pairs (Supplementary Table S1), designed to introduce the following variants in the sequence 
(GeneBank NM_003896.3): c.1024G>A (novel Italian case), c.584G>C and c.601G>A, compound 
substitutions in the Korean siblings (Lee et al. 2016), c.862C>T, Amish and French cases (Simpson et 
al. 2004, Fragaki et al. 2013), c.1063G>A, Afro-American cases (Boccuto et al. 2014). All constructs 
were submitted to direct DNA sequencing. 
WT and mutated pCDNA3-ST3GAL5 plasmids were digested with SgfI and PmeI (sites added to the 
primer sequences, see Supplementary Table S1) and cloned in the corresponding sites of pFN21A 
vector (Promega). This allows to place the coding sequences in frame with the HaloTag.  
Transfections 
For transient transfection, 1x106 HEK-293T cells, grown in DMEM containing 10% Foetal bovine 
serum, were plated in 60 mm dishes. The day after, transfection solutions (0.18 ml each) were 
prepared diluting 3.6 g of a plasmid DNA mixture containing pcDNA3-ST3GAL5 (WT or each variant) 
and pCDNA1-Luciferase (Salvini et al.2001) in a ratio 20:1, w/w, dissolved in simple DMEM and mixed 
with 10.8 l of Fugene-HD (Promega). The mixture was then added dropwise to the plate containing 
the growing medium brought to 1.62 ml. The day after, one ml of complete fresh medium was added 
to each plate. After additional 24 h, transfected and control cells were collected by scraping, washed 
twice with PBS, divided in two aliquots and pelleted. One tenth aliquot was resuspended with 25 l 
of passive lysis buffer (Promega) for luciferase assay, and the remaining aliquot resuspended with 0.1 
M Tris/HCl pH 7.4 containing 0.1% Triton-X100 for sialyltransferase assay. 
For generating stable clones, HEK-293T cells were co-transfected with MluI linearized pFN21A-
ST3GAL5 plasmid and XhoI linearized puromycin resistance plasmid pLKO, using the procedure 
reported (Zulueta et al. 2014). Upon puromycin selection (2.0 g/ml), resistant colonies were 
analysed by fluorescence microscopy on tissue culture slides after treating with the HaloTag-specific 
TMR ligand (Promega), 0.3 ml diluted 1:1000 in the complete growing medium, following the 
manufacture’s procedure. Positive clones were placed in a 12 well plate (about 0.2-0.3 x106 cells per 
well) and the day after treated with TMR (0.6 ml, diluted 1:1000 in complete DMEM) as above, 
trypsinized, washed, resuspended with PBS (0.3 - 0.4 ml) and analysed by flow cytometry as reported 
(Zulueta et al. 2015). 
Enzyme assay 
The reaction mixture contained, in a final volume of 0.03 ml, 0.2 M Cacodylate/HCl buffer pH 6.5, 0.5 
mM CMP-[3H]NeuAc (specific activity 5-10 mCi/mmol), 0.2% Triton-X100, 0.2 mM LacCer, prepared 
as previously reported (Trinchera and Ghidoni 1990), and various amounts of cell homogenate as the 
enzyme source. Blanks were regularly prepared by omitting the acceptor in the reaction mixture. 
LacCer and detergent, or the detergent alone in the blanks, were dissolved in chloroform/methanol, 
2:1 (vol/vol), placed in the reaction tubes and allow to dry overnight before adding the other reaction 
components. Samples were incubated at 37 °C for 1 h. Twenty l of the mixture was spotted on 
Whatman 3MM paper and assayed by descending chromatography in 1% tetraborate (Salvini et al. 
2001). The radioactivity of the appropriate areas was measured by liquid scintillation using 5 ml of 
Instagel (Packard) and the blank values subtracted. Luciferase was assayed as previously reported 
(Mare and Trinchera 2007) using 1 l of a 1:20 dilution in passive lysis buffer of the cell lysate 
obtained as above described, and 25 l of Firefly luciferase assay reagent I (Promega). Protein 
concentration was determined using a BCA assay kit (Pierce). 
Reverse transcription quantitative real-time polymerase chain reaction 
First strand cDNA was synthesized from 1-4 g of total RNA by Moloney Murine Leukemia virus 
reverse transcriptase. Control reactions were prepared by omitting the reverse transcriptase. cDNAs 
(0.2-1.0 l of first strand reactions) were amplified in a volume of 20 µl using Sybr Premix Ex Taq (Tli 
RNase H Plus, Takara), ROX as reference dye and StepOnePlus instrument (Applied Biosystem Life 
Technologies) as reported (Aronica et al. 2017). Primer sequences are listed in Supplementary Table 
S1. Annealing temperature was 60°C. The amounts of amplified target ST3GAL5 cDNA were 
calculated as Ct with respect to GAPDH. 
Western blotting 
For total lysate preparation, washed cell pellets were resuspended in PBS containing HALT protease 
inhibitor cocktail (Thermofisher) and then brought to RIPA buffer (50 mM Tris-HCl pH 7.4, 1% 
Nonidet-P40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl) containing protease inhibitor cocktail, 
and kept on ice with frequent vortexing for 1h. After spinning at 12.000xg for 10 min at 4°C, the clean 
supernatant was removed and stored at -80°C. Aliquots of protein extracts (40 g of protein) were 
separated by 10% SDS-PAGE, transferred to a nitrocellulose membrane using Trans-Blot SD Semi Dry 
Transfer Cell (Bio-Rad Laboratories) and blotted with rabbit polyclonal anti HaloTag (Promega) or 
mouse monoclonal anti -actin (Sigma) followed by secondary peroxidase labeled anti rabbit or anti 
mouse secondary antibody, respectively, according to our published protocol (Faioni et. al. 2014). 
Chemioluminescence was revealed using Alliance imaging system (Uvitec). 
Confocal microscopy 
The N-terminal sequence of WT ST3GAL5 known to act as the signal able to localize the protein to 
the Golgi apparatus (Uemura et al. 2015) was amplified using pcDNA3-ST3GAL5 as template (1 
ng/l), FideliTaq DNA polymerase, and a primer pair deduced from the above paper that also 
contains an NheI site and a Kozak sequence upstream of the ST3GAL5 sequence, and an EcoRI site 
downstream (Supplementary Table S1). Amplification was for 20 cycles and annealing temperature 
64 °C. The DNA product was column purified, digested with NheI and EcoRI, and cloned in the 
corresponding sites of pcDNA3-GFP, generating a fusion protein N-terminalST3GAL5-GFP. 
Recombinant HEK-293T clones expressing WT and ST3GAL5 variants were placed in a 12 well plate 
(0.1 x106 cells) and the day after transfected with the pcDNA3-N-terminalST3GAL5-GFP chimera using 
the conditions reported above and scaling down the volumes from 1.8 ml to 0.6 ml. Twenty-four h 
later, transfected cells were trypsinized and plated on glass coverslip placed at the bottom of the 
wells of a 48 well plate. The day after, the same cells were stained with TMR (1:500 in growing media 
as above reported), washed once with PBS and once with water, and then mounted with Fluor Save 
reagent (Calbiochem) and analyzed under confocal microscopy (Leica TCS SP5, University of Insubria 
Facility). In other experiments, cells (0.1 x106 in 0.2 ml) were directly plated on glass coverslip placed 
at the bottom of the wells of a 48 well plate, and the day after stained with TMR under the 
conditions above reported, but scaling down the volumes. TMR-labeled cells were then washed twice 
with PBS (0.2 ml), fixed with 3.7% formaldehyde in PBS (10 min at RT), washed again twice with PBS, 
permeabilized and blocked with 1%BSA-0.05% Triton-X100 in PBS (0.2 ml twice), and incubated with 
anti-Golgin97 monoclonal antibody (Santa Cruz Biotechnology sc-73619, 1:80 dilution in the last 
buffer) or anti-PDI antibody (Santa Cruz Biotechnology sc-74551, 1:40 dilution in the same buffer), 60 
min at RT. After washing twice with 0.2 ml 1%BSA-0.05% Triton-X100 in PBS, the cells were incubated 
with a secondary FITC-labeled anti mouse IgG antibody (Sigma F0257, 1:80 in the same buffer,) 60 
min at RT. After washing twice with 1% BSA in PBS, once with PBS, and once with water, cells on the 
coverslips were mounted and analyzed as above reported. 
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Legends to figures 
Figure 1. Schematic representation of ST3GAL5 mutations in both cDNA and protein sequences. 
Dotted lines represent the untranslated sequences of exons 1 and 7. 
Figure 2. Clinical presentation of the patient harboring the c.1024G>A (G342S) variant. A: Progression 
with age of mildly dysmorphic facies with fronto-temporal constriction. B: Hyper-pigmented maculae 
on the feet. C: Brain MRI performed at the age of 8 years shows no frank enlargement of 
subarachnoid spaces and ventricular system, nor white matter abnormalities. However, she has 
microcephaly, which demonstrates that the rate of brain growth is slower than normal.  
Figure 3. Detection of GM3 synthase activity. A: HEK-293T cells were transiently co-transfected with 
ST3GAL5 and luciferase expression plasmids. Various amounts of homogenate from transfected cells 
were used as the enzyme source for the detection of luciferase activity or sialyltransferase activity 
towards LacCer (GM3 synthase). Results are the mean ± SD for duplicate assays performed on two 
independent transfections. One unit of luciferase activity corresponds to 1.5 luminometer lectures 
referred to 1 pg of protein lysate. B: Homogenate protein from a HEK-293T clone permanently 
expressing WT ST3GAL5 as a fusion protein with the HaloTag (see Figure 4, brown line) was used at 
various concentrations as enzyme source in the assay. Results are the mean ± SD for triplicate assays. 
C: Homogenate protein from HEK-293T clones permanently expressing ST3GAL5 variants as fusion 
proteins with the HaloTag (see Figure 4, fuchsia lines) was used as enzyme source at high protein 
concentration. For comparison, the enzyme activity measured with two very low concentrations of 
homogenate protein from a WT clone is shown (same clone as in B). Results are the mean ± SD for 
triplicate assays. 
Figure 4. Expression of WT and variant ST3GAL5 in HEK-293T cells permanently transfected with 
cDNAs coding fusion protein with HaloTag. Left panel: Flow cytometry analysis of four independent 
clones obtained upon each transfection. Puromycin-resistant colonies were metabolically stained 
with TMR-ligand, detached with trypsin, and submitted to flow cytometry. Individual clones are 
indicated by distinct colors which were arbitrarily assigned in the following order of fluorescence 
intensity: blue (lower), red, brown, and fuchsia (higher). Single experiments were performed with 
WT or individual-variant clones, including mock-transfected HEK-293T cells (grey peaks) and a single 
WT clone (dotted line peaks) as negative or positive references, respectively. Right panel: cDNA from 
each clone was analyzed by real-time PCR for ST3GAL5 expression using GAPDH as a reference. For 
each clone, the amount of ST3GAL5 transcript, calculated as Ct, was plotted against the 
corresponding mean fluorescence intensity value obtained from the flow cytometry analysis 
reported in the left panels. Lower values correspond to higher expression of the target gene. Color 
codes refer to the colors of the flow cytometry profiles. Results are the mean ± SD for duplicate 
analysis. 
Figure 5. Western blot analysis of HaloTag-ST3GAL5 fusion proteins expressed in HEK-293T clones. 
Membrane proteins were solubilized with RIPA buffer from the same clones as in Fig. 3, separated by 
10% SDS PAGE, blotted onto a nitrocellulose membrane that was stained with rabbit anti-HaloTag 
antibody followed by peroxidase-labeled anti-rabbit secondary antibody. After stripping, the 
membrane was also stained with mouse monoclonal anti--actin followed by peroxidase-labeled 
secondary anti-mouse antibody. Individual clones for WT and each variant are indicated by the same 
color code as in Figure 4. Clones expressing the lowest amounts of tagged protein (blue lines in 
Figure 4) provided identical results under dedicated detection conditions (not shown). 
Figure 6. Confocal microscopy analysis of HEK-293T clones co-expressing ST3GAL5-GFP chimera and 
WT or variant HaloTag-ST3GAL5. HEK-293T clones permanently expressing WT and variant HaloTag-
ST3GAL5 were transiently transfected with a chimera in which GFP was cloned downstream of the N-
terminal region of ST3GAL5 encompassing the signal sequence for Golgi localization end retention. 
Clones depicted as fuchsia in Figures 4 and 5 were used. Transfected cells were then placed on 
coverslip, stained with the Halo-Tag specific ligand TMR, mounted on glass slide, and analyzed by 
confocal microscopy. Red fluorescence represents WT or variant HaloTag-ST3GAL5, green 
fluorescence represents native ST3GAL5. Merged fluorescence become yellow-orange if 
overlapping. Scale bar is 10 m. 
Figure 7. Confocal microscopy analysis of HEK-293T clones expressing WT or variant HaloTag-
ST3GAL5 stained with Golgi or endoplasmic reticulum markers. Clones were seeded on coverslip, 
stained with the Halo-Tag specific ligand TMR, fixed, permeabilized and then incubated with anti-
Golgin97 antibody (Golgi apparatus marker) or anti-PDI antibody (protein disulfide isomerase, 
endoplasmic reticulum marker), followed by a secondary FITC-labeled antibody. Coverslips were 
mounted and analyzed by confocal microscopy as in Figure 6. Scale bar is 10 m. 
Table I. Clinical characteristics of the patient with ST3GAL5-CDG carrying the novel c.1024C>A, p.Gly342Ser (G342S) variant
a
Patient features 
Age General Neurologic Hearing Laboratory findings (normal values) 
Neonatal Patent foramen ovale Hypotonia 
Hearing screening ambiguous 
not passed 
Neonatal jaundice , bilirubin up to 22 mg/dL 
4-12
months 
Failure to thrive, 
strabismus, no eye 
contact 
Smiling after 5 months, head 
control after 7 months; 
turning from prone to supine 
at 18 months 
Bilateral hearing loss by 





No clinical seizure but 
multifocal epileptiform activity 
Blood lactate 4061 mol/L (500-1800) 
Blood pyruvate 278 mol/L (50-35) 
Urinary lactate 403 g/mg creatine (<80)  
Plasma lactate dehydrogenase 670 U/L (<480) 
Plasma alanine aminotransferase 40 U/L (<35) 
Total /conjugated bilirubin 2.4/0.5 mg/dL (<1.5/0.4) 
1-2 years
Seizure treated  successfully 
with Phenobarbital 
Cultured fibroblasts and muscle biopsy: 
pyruvate kinase deficiency (30% of controls), 







Status epilepticus treated 
successfully with Topiramate 
in addition to Phenobarbital  





Weight: 18 kg (- 4.7 SD) 
Length: 119 cm (-6.1 SD) 
Head circumference: 
50.5 cm (-3 SD) 
Continuous apparently 
involuntary movements (Supp. 
Video)  
MRI normal 
aThe patient is also carrying the homozygous variant Q7V in the HBB g
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 

